Edward C. English - 09 Nov 2022 Form 3 Insider Report for Xilio Therapeutics, Inc. (XLO)

Role: Principal Accounting Officer
Signature: /c/ Edward C. English
Issuer symbol: XLO
Transactions as of: 09 Nov 2022
Net transactions value: $0
Form type: 3
Filing time: 16 Nov 2022, 15:16:40 UTC
Next filing: 04 Jan 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	XLO	Common Stock						6,002	09 Nov 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	XLO	Stock Option (right to buy)							09 Nov 2022	Common Stock	16,428	$5.89	Direct	F1
holding	XLO	Stock Option (right to buy)							09 Nov 2022	Common Stock	6,891	$5.89	Direct	F2
holding	XLO	Stock Option (right to buy)							09 Nov 2022	Common Stock	20,828	$10.07	Direct	F3
holding	XLO	Stock Option (right to buy)							09 Nov 2022	Common Stock	9,050	$5.51	Direct	F4
holding	XLO	Stock Option (right to buy)							09 Nov 2022	Common Stock	20,200	$12.66	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The option was granted on February 8, 2021. On March 1, 2021, 1/48th of the shares underlying the option vested with the remainder scheduled to vest in equal monthly installments on the 1st day of each month thereafter through February 1, 2025.
F2	The option was granted on March 11, 2021. On April 1, 2021, 1/48th of the shares underlying the option vested with the remainder scheduled to vest in equal monthly installments on the 1st day of each month thereafter through March 1, 2025.
F3	The option was granted on June 17, 2021. On July 1, 2021, 1/48th of the shares underlying the option vested with the remainder scheduled to vest in equal monthly installments on the 1st day of each month thereafter through June 1, 2025.
F4	The option was granted on July 23, 2020. On September 30, 2020, 25% of the shares underlying the option vested with the remainder scheduled to vest in equal monthly installments on the last day of each month thereafter through September 30, 2023.
F5	The option was granted on February 22, 2022. On March 1, 2022, 1/48th of the shares underlying the option vested with the remainder scheduled to vest in equal monthly installments on the 1st day of each month thereafter through February 1, 2026.